NeoStem’s Subsidiary, Progenitor Cell Therapy, Enters Into a Services Agreement with Sentien Biotechnologies, Inc. NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy LLC (PCT), announced the execution of a Services Agreement with Sentien Biotechnologies, Inc. (Sentien) under which PCT will provide services to support Sentien’s development of its cell therapy product, including technology transfer, staff training, and manufacturing. [NeoStem, Inc.] Press Release Stemedica Enters into Stem Cell Licensing Agreement with Kalbe Farma Stemedica Asia PTE, LTD, a wholly owned subsidiary of Stemedica Cell Technologies, Inc. announced that the Company has entered into a definitive licensing agreement with the Stem Cell and Cancer Institute, a division of PT Kalbe Farma Tbk. (Kalbe). [Stemedica Cell Technologies, Inc.] Press Release Advaxis and FusionVax Sign a Memorandum of Understanding for the License of Advaxis’ ADXS-HPV in Asia Advaxis, Inc. announced that it has entered into a Memorandum of Understanding with FusionVax, Inc. setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia. [Advaxis, Inc.] Press Release ACT Initiates Higher-Dosage Patient Treatment in European Clinical Trial for Macular Degeneration Advanced Cell Technology, Inc. (ACT) announced treatment of the first patient in the third dosage cohort, and seventh patient overall, in its European Phase I clinical trial for Stargardt’s macular dystrophy using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was injected with 150,000 hESC-derived RPE cells, as compared with the 100,000-cell dose used in patients of the second cohort. [Advanced Cell Technology, Inc.] Press Release Mesoblast Reports Positive Interim Results in Phase II Trial of Proprietary Adult Stem Cells for Intervertebral Disc Repair Regenerative medicine company Mesoblast Limited announced that all 100 patients in its Phase II clinical trial of its proprietary mesenchymal precursor cells for intervertebral disc repair had completed six months of follow-up, the endpoint at which data will be evaluated for progression to Phase III. [Mesoblast Limited] Press Release Humacyte Announces Significant Clinical Milestones in Its Novel Bioengineered Blood Vessel Technology Humacyte, Inc. announced the accomplishment of significant milestones in the clinical development of its innovative bioengineered blood vessel technology – the first off-the-shelf, human-derived, artificial blood vessels. [Humacyte, Inc.] Press Release MRI Interventions’ ClearPoint(R) System Helps Advance Brain Cancer Clinical Trial of Investigational Gene Therapy Drug Toca 511, Demonstrates Benefits of MRI-Guided Drug Delivery MRI Interventions, Inc. announced that its ClearPoint® Neuro Intervention System is advancing the minimally-invasive precision delivery of the investigational gene therapy drug Toca 511 into malignant brain tumors. The procedure is being performed under real-time visualization and direct magnetic resonance imaging (MRI) guidance at select clinical trial sites. [MRI Interventions, Inc.] Press Release UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease Protalix BioTherapeutics, Inc. announced that the Mexican Federal Commission for the Protection against Sanitary Risk and the Public Health Institute of Chile have both granted regulatory approval to UPLYSO™ (alfataliglicerase) for the long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease. UPLYSO is the first plant cell-based enzyme replacement therapy for the treatment of Gaucher disease. [Protalix BioTherapeutics, Inc.] Press Release American CryoStem Marks Major Global Expansion Milestone: Receives First International Shipment of Adipose Tissue for Processing and Cryo-Storage from Hong Kong American CryoStem Corporation announced receipt of its first commercial international shipment of adipose tissue for processing and long term cryo-storage. [American CryoStem Corporation] Press Release |